Elevation Oncology, Inc. (ELEV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELEV Stock Price Chart Interactive Chart >
ELEV Price/Volume Stats
| Current price | $1.00 | 52-week high | $5.20 |
| Prev. close | $1.00 | 52-week low | $0.72 |
| Day low | $0.96 | Volume | 23,003 |
| Day high | $1.03 | Avg. volume | 152,335 |
| 50-day MA | $0.98 | Dividend yield | N/A |
| 200-day MA | $1.48 | Market Cap | 23.30M |
Elevation Oncology, Inc. (ELEV) Company Bio
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Latest ELEV News From Around the Web
Below are the latest news stories about ELEVATION ONCOLOGY INC that investors may wish to consider to help them evaluate ELEV as an investment opportunity.
Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNEW YORK, Jan. 9, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that… |
Elevation Oncology CEO resigns as part of company prioritization effortElevation Oncology (ELEV) CEO Shawn Leland has resigned amid a company effort to realign resources and prioritize pipeline assets. |
Elevation Oncology Inc. (NASDAQ:ELEV) Shares Rebounded -2.38% From Their Lows – But Can They Continue?In recent trading session, Elevation Oncology Inc. (NASDAQ:ELEV) saw 0.66 million shares changing hands at last check today with its beta currently measuring 0. Company’s recent per share price level of $0.84 trading at -$0.21 or -20.05% at last check today assigns it a market valuation of $25.98M. That most recent trading price of ELEV’s … Elevation Oncology Inc. (NASDAQ:ELEV) Shares Rebounded -2.38% From Their Lows – But Can They Continue? Read More » |
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO TransitionElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to prioritize key research and development efforts to advance EO-3021, its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin18.2, and other pipeline programs including those through its existing partnership with Caris |
Elevation Oncology to Participate at the JMP Securities Hematology and Oncology SummitNEW YORK, Nov. 30, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Founder and Chief… |
ELEV Price Returns
| 1-mo | 5.26% |
| 3-mo | -13.79% |
| 6-mo | -21.26% |
| 1-year | -77.12% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 5.26% |
| 2022 | -84.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...